Literature DB >> 9817152

Systemic markers of inflammation in stable bronchiectasis.

C B Wilson1, P W Jones, C J O'Leary, D M Hansell, R B Dowling, P J Cole, R Wilson.   

Abstract

Patients with bronchiectasis have an active local and systemic inflammatory response during infective exacerbations. Systemic markers of inflammation were investigated during a stable phase of their illness, because continued inflammation could affect their general health and be involved in disease progression. The relationship between levels of various systemic markers of inflammation and extent of disease on computed tomographic scan, lung function, sputum bacteriology and health related quality of life (HRQoL) was investigated in 87 noncystic fibrosis bronchiectasis patients. Several markers were elevated and correlated with the extent of disease and poor lung function. The total white cell count, neutrophil count and erythrocyte sedimentation rate correlated with both disease measures. Sputum bacteriology did not correlate with inflammation markers and patients with positive and negative cultures were similar. C-reactive protein and total white cell count correlated with some components of a disease-specific HRQoL questionnaire. In conclusion, patients with bronchiectasis in a stable phase have raised systemic markers of inflammation. Some markers, particularly the neutrophil count, correlate with disease severity. This result is in keeping with the hypothesis that the level of inflammation determines disease progression and health status.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817152     DOI: 10.1183/09031936.98.12040820

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  20 in total

1.  Testing bias in clinical databases: methodological considerations.

Authors:  Karin J Velthove; Hubert Gm Leufkens; Patrick C Souverein; René C Schweizer; Wouter W van Solinge
Journal:  Emerg Themes Epidemiol       Date:  2010-05-14

Review 2.  Severe bronchiectasis.

Authors:  Brian M Morrissey; Samuel J Evans
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

3.  Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients.

Authors:  Pieter Christian Goeminne; Hans Scheers; Ann Decraene; Sven Seys; Lieven Joseph Dupont
Journal:  Respir Res       Date:  2012-03-16

4.  Airway inflammation contributes to health status in COPD: a cross-sectional study.

Authors:  Jiska B Snoeck-Stroband; Dirkje S Postma; Thérèse S Lapperre; Margot M E Gosman; Henk A Thiadens; Henk F Kauffman; Jacob K Sont; Désirée F Jansen; Peter J Sterk
Journal:  Respir Res       Date:  2006-11-30

5.  The role of the high-sensitivity C-reactive protein in patients with stable non-cystic fibrosis bronchiectasis.

Authors:  Meng-Heng Hsieh; Yueh-Fu Fang; Guan-Yuan Chen; Fu-Tsai Chung; Yuan-Chang Liu; Cheng-Hsien Wu; Yu-Chen Chang; Horng-Chyuan Lin
Journal:  Pulm Med       Date:  2013-12-07

6.  Is There a Correlation between New Scoring Systems and Systemic Inflammation in Stable Bronchiectasis?

Authors:  Hikmet Coban; Adil Can Gungen
Journal:  Can Respir J       Date:  2017-11-15       Impact factor: 2.409

Review 7.  Neurological and Sleep Disturbances in Bronchiectasis.

Authors:  Chun Seng Phua; Tissa Wijeratne; Conroy Wong; Lata Jayaram
Journal:  J Clin Med       Date:  2017-11-30       Impact factor: 4.241

8.  The immune response and its therapeutic modulation in bronchiectasis.

Authors:  Massoud Daheshia; James D Prahl; Jacob J Carmichael; John S Parrish; Gilbert Seda
Journal:  Pulm Med       Date:  2012-10-10

9.  Increased Peripheral Blood Pro-Inflammatory/Cytotoxic Lymphocytes in Children with Bronchiectasis.

Authors:  G Hodge; J W Upham; A B Chang; K J Baines; S T Yerkovich; S J Pizzutto; S Hodge
Journal:  PLoS One       Date:  2015-08-10       Impact factor: 3.240

10.  Bronchiectasis and the risk of cardiovascular disease: a population-based study.

Authors:  Vidya Navaratnam; Elizabeth R C Millett; John R Hurst; Sara L Thomas; Liam Smeeth; Richard B Hubbard; Jeremy Brown; Jennifer K Quint
Journal:  Thorax       Date:  2016-08-29       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.